NYSE - Delayed Quote USD

Merck & Co., Inc. (MRK)

Compare
117.17 -0.06 (-0.05%)
At close: September 20 at 4:01 PM EDT
117.25 +0.08 (+0.07%)
After hours: September 20 at 7:52 PM EDT
Loading Chart for MRK
DELL
  • Previous Close 117.23
  • Open 117.27
  • Bid 117.25 x 900
  • Ask 116.97 x 900
  • Day's Range 116.47 - 117.50
  • 52 Week Range 99.14 - 134.63
  • Volume 21,185,182
  • Avg. Volume 9,922,806
  • Market Cap (intraday) 297.004B
  • Beta (5Y Monthly) 0.40
  • PE Ratio (TTM) 21.70
  • EPS (TTM) 5.40
  • Earnings Date Oct 31, 2024
  • Forward Dividend & Yield 3.08 (2.63%)
  • Ex-Dividend Date Sep 16, 2024
  • 1y Target Est 139.94

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

www.merck.com

70,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MRK

View More

Performance Overview: MRK

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MRK
9.53%
S&P 500
19.55%

1-Year Return

MRK
12.03%
S&P 500
28.32%

3-Year Return

MRK
78.43%
S&P 500
28.64%

5-Year Return

MRK
70.23%
S&P 500
89.66%

Compare To: MRK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MRK

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    297.00B

  • Enterprise Value

    323.44B

  • Trailing P/E

    21.70

  • Forward P/E

    11.70

  • PEG Ratio (5yr expected)

    0.08

  • Price/Sales (ttm)

    4.78

  • Price/Book (mrq)

    6.81

  • Enterprise Value/Revenue

    5.18

  • Enterprise Value/EBITDA

    15.71

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.99%

  • Return on Assets (ttm)

    11.38%

  • Return on Equity (ttm)

    33.38%

  • Revenue (ttm)

    62.48B

  • Net Income Avi to Common (ttm)

    13.74B

  • Diluted EPS (ttm)

    5.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.35B

  • Total Debt/Equity (mrq)

    86.57%

  • Levered Free Cash Flow (ttm)

    11.79B

Research Analysis: MRK

View More

Company Insights: MRK

Research Reports: MRK

View More

People Also Watch